Yaya za a bi da COVID-19? Fesa hanci yana da kashi 93%

Wani sabon magani na hanci wanda aka haɓaka don haɓaka tsarin garkuwar jikin ɗan adam don yaƙar mura da mura ya tabbatar da nasara sosai wajen rage sakamakon gwajin kwafi na COVID-19, wanda aka fitar a yau, ya bayyana.

Sabon samfurin, INNA-051, wanda kamfanin fasahar kere-kere ta Australiya, Ena Respiratory, ya kera, ya rage kwafi da kashi 96 cikin XNUMX a wani binciken dabba na zinari karkashin jagorancin Mataimakin Darakta na Kiwon Lafiyar Jama'a na Ingila (PHE), Farfesa Miles Carroll, kuma aka buga a yau. akan shafin bincike kafin buguwar halittu, medRxiv.

Filin INNA-051 yana aiki ta hanyar ƙarfafa tsarin rigakafi na asali, layin farko na kariya daga mamayewar ƙwayoyin cuta cikin jiki. Ta hanyar haɓaka martanin rigakafi ta wannan hanyar tare da INNA-051 kafin kamuwa da cuta, ikon ƙwayar cuta ta COVID-19 don cutar da dabbobi da yin kwafi ya ragu sosai da binciken PHE ya nuna. Binciken ya ba da shaida cewa za a iya amfani da INNA-051 a matsayin hanyar da ta dace ta rigakafin rigakafin cutar, wanda ya dace da shirye-shiryen rigakafin.

"Mun yi mamakin yadda maganinmu ya yi tasiri," in ji Ena Manajan Daraktan Numfashi, Dokta Christophe Demaison. "Ta hanyar haɓaka martanin rigakafi na dabi'a na ferrets tare da jiyyarmu, mun ga saurin kawar da kwayar cutar."

“Idan mutane suka amsa ta irin wannan hanya, amfanin jiyya ya ninka biyu. Mutanen da suka kamu da kwayar cutar za su iya kawar da ita cikin sauri, tare da tabbatar da cewa cutar ba ta ci gaba ba fiye da ƙananan alamu. Wannan yana da mahimmanci musamman ga masu rauni na al'umma. Bugu da kari, saurin wannan martanin yana nufin cewa masu kamuwa da cutar ba za su iya ba da ita ba, ma'ana a gaggauta dakatar da watsawar al'umma."

Ena Respiratory ya haɓaka AU $ 11.7m daga masu saka hannun jari na Ostiraliya kuma, bisa ga nasarar nazarin guba da kuma yarda da tsari, kamfanin zai iya kasancewa a shirye don gwada INNA-051 a cikin gwajin ɗan adam a cikin ƙasa da watanni huɗu. 

An jagoranci saka hannun jari da goyan baya don haɓaka aikin novel therapy daga Asusun Kasuwancin Bincike na Kiwon Lafiya na Australiya (MRCF),  Australia mafi girman asusun saka hannun jari na kimiyyar rayuwa wanda Brandon Capital ke gudanarwa, tare da haɗin gwiwa daga asusun kasuwancin jami'a Uniseed. Kamfanin yana neman ƙarin kudade cikin gaggawa don haɓaka ci gaban asibiti na feshin hanci da rarrabawar duniya. 

Dr Chris Nave, Shugaba na MRCF kuma wanda ya kafa Brandon Capital, ya ce waɗannan sakamako masu ban sha'awa na nufin INNA-051 ta kasance gaba mai ban sha'awa a fagen fama don doke COVID-19. "Muna yin duk abin da za mu iya don tallafa wa Ena Respiratory da ƙoƙarinsa na samun ƙarin saka hannun jari don haɓaka haɓakawa da gwajin maganin a cikin mutane. Yayin da allurar a ƙarshe ita ce babbar hanyar magance COVID-19, gwamnatoci suna buƙatar haɓaka hanyoyin jiyya daban-daban don tabbatar da cewa suna da zaɓi iri-iri, idan maganin ya gagara ko kuma ya ɗauki tsawon lokaci don haɓakawa. ”

INNA-051 karamin kwayoyin halitta ne na roba kuma za'a gudanar da kansa ta hanyar feshin hanci mai saukin amfani, ana sha sau daya ko sau biyu a mako, tare da daukar matakin kusan nan take. Idan gwaje-gwajen ɗan adam sun yi nasara kuma, idan aka ba da buƙatun da ba a taɓa gani ba na magunguna don yaƙar COVID-19, ana iya kera wannan maganin rigakafin rigakafi cikin sauri a sikelin kuma ana samun amfani da shi nan ba da jimawa ba.

"Wannan babban ci gaba ne yayin da duniya ke fafatawa don nemo mafita don dakatar da watsa COVID-19 da kamuwa da cutar a cikin hadarin," in ji Farfesa Roberto Solari kwararre na numfashi, mai ba da shawara ga Ena Respiratory da Farfesa mai ziyara a Kwalejin Imperial ta London. "Mafi ban sha'awa shine ikon INNA-051 don rage matakan ƙwayoyin cuta a cikin hanci da makogwaro, yana ba da bege cewa wannan maganin zai iya rage yaduwar COVID-19 ta hanyar masu kamuwa da cuta, musamman waɗanda ke iya zama presymptomatic ko asymptomatic kuma don haka ba su san suna da kamuwa da cuta ba. ,” in ji Farfesa Solari.

INNA-051 tana ba da bege na gaske ga waɗanda ke kan gaba wajen yaƙi da COVID-19, in ji Dr Chris Smith, Daraktan Hukumar Numfashi na Ena, kuma Babban Manajan Zuba Jari a Brandon Capital. "Magungunan yana ba da babbar dama don kare mafi rauni, gami da waɗanda ke da yanayin numfashi da kuma tsofaffi, inda alluran rigakafin ba su da tasiri." 

INNA-051 tana cikin haɓakawa kafin barkewar COVID-19 don haɓaka juriya ga manyan cututtukan ƙwayar cuta na numfashi. Ba kamar alluran rigakafin da aka yi niyya ga wani nau'i na musamman ba, INNA-051, an tsara su don yin tasiri ga kowane nau'in cututtukan numfashi. 

Dr Smith ya ci gaba da cewa "Maganin hancinmu yana da damar ban mamaki don yaƙar COVID-19 da annoba a nan gaba." Mun san cewa alurar riga kafi sau da yawa shine mafi kyawun hanyar magance cututtukan ƙwayoyin cuta na numfashi, amma wannan hanyar sau da yawa tana zuwa tare da ƙalubale yayin da allurar rigakafi ke haifar da takamaiman martani a cikin tsarin rigakafi wanda ba zai yi tasiri a kan maye gurbi na gaba na ƙwayar cuta ba. INNA-051 tana amfani da martanin rigakafin da ba na musamman ba wanda ke nufin yana da tasiri a kan nau'ikan ƙwayoyin cuta. 

"A matsayin mai saka hannun jari na asali tare da Uniseed, MRCF ta ga babban yuwuwar a cikin INNA-051, kafin zamanin COVID-19, don gudanar da barkewar cutar kwayar cutar numfashi, kamar yadda muke fama da ita a halin yanzu, kodayake farkon mayar da hankali kan mu shine mura," in ji Dr Nave. . "Yanzu mun yi farin ciki da samun damar karkata kokarin zuwa yaki da COVID-19. Maganin yana da gagarumin yuwuwar, ba wai kawai a kan wannan cutar ba har ma da taka muhimmiyar rawa a barkewar cutar numfashi ta kwayar cutar nan gaba."

Marubutan binciken sun hada da masana kimiyya daga Kiwon Lafiyar Jama'a Ingila (PHE), Ena Respiratory, da manyan kungiyoyin bincike na Ostiraliya, Cibiyar Binciken Kiwon Lafiya ta Hunter, Newcastle da Jami'ar Melbourne. 

Shugaban Uniseed Dr Peter Devine  ya kara da cewa, “Waɗannan sakamako ne masu ban sha'awa kuma suna nuna yuwuwar amfanin asibiti na maganin Ena a cikin maganin COVID-19 wanda zai iya buƙatar hanyoyin jiyya da yawa. Har ila yau, ya jaddada darajar sauƙaƙe kasuwancin bincike na farko, wanda zai iya ci gaba da haifar da tasiri a duniya."

Game da Ena Respiratory

Ena Respiratory kamfani ne na Ena Therapeutics, wanda ke da niyyar canza magani da rigakafin cututtukan numfashi a cikin mutanen da ke cikin haɗari.

Ena Respiratory yana haɓaka novel, roba innate immunomodulators don rigakafin ƙwayoyin cuta na numfashi da ƙwayoyin cuta. Kamfanin yana cikin Melbourne da Sydney, Ostiraliya. Ena Therapeutics ya sami damar saka hannun jari na Series A daga Brandon Capital sarrafa Asusun Kasuwancin Binciken Kiwon Lafiya (MRCF) da Uniseed.

Game da INNA-051

Dan takarar jagoran Ena Respiratory, INNA-051 na roba ne, mai pegylated TLR2/6 agonist. INNA-051 an haɓaka shi don isar da kai tsaye zuwa hanyoyin iska (ta hanyar feshin hanci sau ɗaya/biyu a mako) don a kai hari ga wurin farko na yawancin cututtukan numfashi, gami da COVID-19, mura da rhinovirus. Gudanar da numfashi na sama na Ena Respiratory's pegylated TLR2/6 agonists yana haifar da kunna maɓalli da yawa, ingantattun hanyoyin kariya na rigakafi waɗanda ke cikin rigakafin rigakafin cutar. INNA-051 ya dogara ne akan binciken da Farfesa David Jackson da tawagarsa suka yi. Farfesa Jackson ya jagoranci dakin gwaje-gwaje a Sashen Microbiology da Immunology a Cibiyar Kula da Kamuwa da Kariya ta Peter Doherty, Jami'ar Melbourne. 

An nuna fa'idar antiviral mai fa'ida ta Ena Respiratory's pegylated TLR2/6 agonists a cikin tsarin dabbobi na ƙwayoyin cuta na numfashi, gami da mura da rhinovirus (sanyi na yau da kullun) da samfuran kamuwa da cuta na biyu.

An tabbatar da ingancin INNA-051 game da COVID-19 a cikin samfurin ƙalubale na ƙungiyar da Farfesa Miles Carroll ke jagoranta a Kiwon Lafiyar Jama'a ta Ingila. A cikin wannan binciken INNA-051 an gudanar da shi azaman rigakafi. A cikin mafi kyawun tsarin tsarin, bayan kwanaki 5 bayan bayyanar cutar ta COVID-19, dabbobin INNA-051 da aka yi wa magani sun sami raguwar ƙwayoyin cuta a cikin makogwaro (raguwar kashi 96%) da wankin hanci (raguwar kashi 93%) idan aka kwatanta da dabbobin da ba a kula da su ba, duk da sosai matakan kamuwa da ƙwayoyin cuta (kimanin ƙwayoyin ƙwayoyin cuta miliyan 5 an gudanar da su a cikin waɗannan karatun).

Game da Asusun Kasuwancin Binciken Kiwon Lafiya (MRCF) da Brandon Capital Partners 

Brandon Capital Partners babban kamfani ne na kamfani wanda ke kula da Asusun Kasuwancin Bincike na Kiwon Lafiya (MRCF), Australia  da  New Zealand mafi girman asusun saka hannun jari na rayuwa. MRCF haɗin gwiwa ne na musamman tsakanin manyan kudaden tallafin Australiya, gwamnatocin Australiya da New Zealand , gwamnatocin jahohin Australiya da manyan cibiyoyin binciken likita sama da 50 da asibitocin bincike. MRCF tana goyan bayan haɓakawa da tallace-tallace na binciken ilimin halittu na farko-farko wanda ya samo asali daga ƙungiyoyin bincike na memba, yana ba da babban jari da ƙwarewa don jagorantar ci gaba mai nasara na sabbin hanyoyin kwantar da hankali. MRCF ta tallafa wa kamfanoni sama da 45 da suka fara farawa har zuwa yau, yawancin su MRCF ne suka kafa su. 

Game da Uniseed

Uniseed shine asusun tallata matakin farko mafi tsawo a Ostiraliya wanda ke sanya hannun jari a cikin bincike da ke fitowa daga manyan kungiyoyin bincike guda biyar - Jami'ar Queensland, Jami'ar Sydney, Jami'ar New South Wales, Jami'ar Melbourne da CSIRO. Uniseed asusun haɗin gwiwa ne, mallakar ƙungiyoyin bincike, don ƙungiyoyin bincike. Asusun yana sauƙaƙe tallan tallace-tallace na abokan bincikensa mafi kyawun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun masu bincike, da kuma samar da zuba jari da aka yi niyya a cikin samfurori da fasaha. Uniseed ya tallafa wa kamfanoni masu tasowa 57 har zuwa yau, kasancewa mai saka jarin iri a yawancin waɗannan.

Kara: www.uniseed.com